Intuitive Surgical, Inc. Q2 2026 Earnings Recap

Shares dropped 11.2% as investors reacted negatively to signs of US procedural growth deceleration and an increasingly cautious outlook amid persistent challenges in China’s market and pricing pressures.

Key Takeaways

• US da Vinci procedure growth slowed to 12%, below prior trends, with moderation mainly in deferrable procedures, linked to patient coverage and premium changes.
• China remains a challenging market due to reduced tender activity, domestic competition, and policy-driven pricing pressure.
• Global installed base expanded, with 468 da Vinci systems and 55 ION systems placed, alongside consistent 16% growth in total procedures.
• Single port (SP) procedures surged 61%, supported by adoption in Korea and the US and new product enhancements.
• Management projects cost reduction via extended use of select instruments to expand adoption, particularly in cost-sensitive markets, but these initiatives may pressure near-term margins.